Data Sheet 6: A Case Report on TMEp-CI-M Platform for Refractory SCLC

A single-case report from figshare, authored by Yating Wu and last updated in June 2026, details the treatment of a 60-year-old male with PD-L1-negative extensive-stage small-cell lung cancer and brainstem metastasis. The report describes the use of the TMEp-CI-M platform, which integrates tumor microenvironment priming, checkpoint inhibition, and microbiome modulation. The patient achieved no evidence of disease for over 20 months following six treatment cycles.

Use Cases

• Analyze the efficacy of a multi-modal immunotherapy platform based on the described TMEp-CI-M regimen.
• Study biomarker response in a rare cancer presentation based on the reported ProGRP level normalization from 1803 pg/mL to 23.71 pg/mL.
• Investigate durable treatment responses in immunologically 'cold' tumors based on the reported over 20 months of disease-free survival.
• Review the safety profile of a combined therapy approach based on the reported Grade 1 hypothyroidism as the primary adverse event.

Strengths

• Report includes specific biomarker levels (ProGRP) before and after treatment, showing a drop from 1803 pg/mL to 23.71 pg/mL.
• Provides a detailed, long-term clinical outcome with over 20 months of disease-free survival documented.
• Describes a specific, multi-phase treatment regimen (TMEp, CI, M) with named components like cadonilimab and anlotinib.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is a single-case report, limiting statistical power and generalizability.

Provenance

Source

figshare, author Yating Wu.

Collection Method

Clinical case report.

Time Range

Covers a treatment and follow-up period resulting in over 20 months of disease-free survival.

Freshness

Last updated 2026-06-01 05:18:37; freshness should be verified.